A5051880949- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Urinary Bladder and Prostate Research
- Urinary and Genital Oncology Studies
- Renal and related cancers
- Hormonal and reproductive studies
- Statistical Methods in Clinical Trials
- Pelvic floor disorders treatments
- Radiomics and Machine Learning in Medical Imaging
- Metabolism and Genetic Disorders
- Urinary Tract Infections Management
- Medical Imaging Techniques and Applications
- Multiple Myeloma Research and Treatments
- Biochemical effects in animals
- Renal and Vascular Pathologies
- Advanced Radiotherapy Techniques
- Genital Health and Disease
- Pediatric Urology and Nephrology Studies
- Cardiac, Anesthesia and Surgical Outcomes
Universität Hamburg
2014-2025
University Medical Center Hamburg-Eppendorf
2014-2025
University Hospital Frankfurt
2018-2025
Goethe University Frankfurt
2018-2025
Martini-Klinik
2017-2025
Klinik und Poliklinik für Urologie
2022-2024
MVZ - Kurfürstendamm
2022
Witten/Herdecke University
2022
TU Dresden
2022
Heinrich Heine University Düsseldorf
2017
Abstract Background In-hospital mortality and complication rates after partial radical nephrectomy in patients with history of heart-valve replacement are unknown. Patients Methods Relying on the National Inpatient Sample (2000–2019), kidney cancer undergoing or were stratified according to presence absence replacement. Multivariable logistic Poisson regression models addressed adverse hospital outcomes. Results Overall, 39,673 underwent versus 94,890 nephrectomy. Of those, 248 (0.6%) 676...
PurposeTo assess in-hospital mortality and complication rates after radical cystectomy (RC) in patients with history of heart-valve replacement.Materials methodsUsing the National Inpatient Sample (2000–2019), non-metastatic bladder cancer undergoing RC were stratified according to replacement. Regression models (RM) predicted hospital outcomes.ResultsOf 25,535 patients, 250 (1.0%) harbored Heart-valve replacement older (median 74 vs. 70 years), more frequently male (87.2 80.6%), had...
To evaluate the impact of prostate-specific antigen (PSA) nadir, PSA response and time to nadir (TTN) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) era combination therapies.
With approval of novel systemic therapies within the past decade for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer, patients may receive several therapy lines. However, use these treatments is under an ongoing change. We investigated contemporary treatment trends progression-free (PFS) overall (OS) survival different
Rationale: [177Lu]Lutetium prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA) is EMA-approved for certain indications in metastatic castration resistant prostate cancer (mCRPC). However, cancer-control outcomes specific and trial-underrepresented subgroups are scant. Methods: We relied on the FRAMCAP database to elaborate progression-free (PFS) overall (OS) survival elderly (≥75 yrs), frail (ECOG status ≥1) mCRPC patients or those with cardiovascular disease (CVD)...
Prostate cancer is a major health concern in aging men. Paralleling an society, prostate prevalence increases emphasizing the need for efficient diagnostic algorithms.Retrospectively, 106 tissue samples from 48 patients (mean age, [Formula: see text] years) were included study. Patients suffered (n = 38) or benign prostatic hyperplasia 10) and treated with radical prostatectomy Holmium laser enucleation of prostate, respectively. We constructed microarrays (TMAs) comprising representative...
To assess cancer-specific mortality (CSM) and other-cause (OCM) rates in patients with rare histological prostate cancer subtypes.
Currently available post hoc phase 3 trial-derived data suggest better cancer-control outcomes in apalutamide-treated metastatic hormone-sensitive prostate cancer (mHSPC) patients achieving an (ultra)low prostate-specific antigen (PSA) nadir. This study aims to validate ultralow PSA nadir cutoffs.
Purpose: Acoustic Radiation Force Impulse Imaging (ARFI) is a new ultrasound elastography technology (Siemens ACUSON S2000 Virtual Touch™ Tissue Quantification), which integrated in conventional equipment. In preliminary studies, ARFI s
No AccessJournal of UrologyAdult Urology1 Feb 2015Salvage Lymph Node Dissection for Nodal Recurrence Prostate Cancer after Radical Prostatectomy Derya Tilki, Philipp Mandel, Flora Seeliger, Alexander Kretschmer, Karl, Süleyman Ergün, Michael Seitz, and Christian G. Stief TilkiDerya Tilki Department Urology, Ludwig-Maximilians-University, Klinikum Grosshadern, Munich, Germany Martini-Clinic Center University Hospital Hamburg-Eppendorf, Hamburg, , MandelPhilipp Mandel SeeligerFlora Seeliger...
The CAPRA-S score predicts prostate cancer recurrence based on pathological information from radical prostatectomy. To our knowledge has never been externally validated in a European cohort. We independently single institution database.The study cohort comprised 14,532 patients treated with prostatectomy between January 1992 and August 2012. Prediction of biochemical recurrence, metastasis specific mortality by was assessed Kaplan-Meier analysis the c-index. performance to predict evaluated...
Abstract Objectives To analyze the performance of radiological assessment categories and quantitative computational analysis apparent diffusion coefficient (ADC) maps using variant machine learning algorithms to differentiate clinically significant versus insignificant prostate cancer (PCa). Methods Retrospectively, 73 patients were included in study. The (mean age, 66.3 ± 7.6 years) examined with multiparametric MRI (mpMRI) prior radical prostatectomy ( n = 33) or targeted biopsy 40). index...
Background To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) era combination therapies for mHSPC. Material and Methods Of 213 mHSPC diagnosed between 01/2013-12/2020 who subsequently developed resistant (mCRPC), 204 eligible were analyzed after having applied exclusion criteria. classified into TTCR <12, 12-18, 18-24, >24 months regarding OS. Moreover, further OS analyses...
Abstract Background Myelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events patients undergoing RLT with 177 Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). The contribution pretreatment risk factors cumulative treatment activity taken into account specifically. Methods was performed 140 receiving total 497 cycles. A mean 6.9 $$\pm$$...